宏观了解专利过程

2015-04-22 MedSci MedSci原创

引言:建议委托代理人完成专利申请工作;原因体现在:专利申请文件的撰写以及答复审查意见的形式较为专业;另外,专利申请提交方式、专利费用的缴纳以及各类程序的时间规定等方面较为繁琐。如下从专利申请—专利审查—专利授权—专利权维护—专利权终止等方面进行概述。一、专利申请前的准备工作申请人将自己的技术方案,以技术交底书的方式呈现给代理人,并提供相关基础信息,签订委托书和代理合同等文件;申请人支付代理服务费和

引言:


建议委托代理人完成专利申请工作;原因体现在:专利申请文件的撰写以及答复审查意见的形式较为专业;另外,专利申请提交方式、专利费用的缴纳以及各类程序的时间规定等方面较为繁琐。

如下从专利申请—专利审查—专利授权—专利权维护—专利权终止等方面进行概述。

一、专利申请前的准备工作

申请人将自己的技术方案,以技术交底书的方式呈现给代理人,并提供相关基础信息,签订委托书和代理合同等文件;申请人支付代理服务费和专利局收取的官方费用。

二、专利申请文件的撰写和提交

代理人会将技术方案形成符合专利法规定的专利申请文件(包括权利要求书、说明书、说明书附图、摘要、摘要附图等);申请文件内容经申请人确认后,代理人制作电子提交格式文件,上报至专利局。

三、专利的官方受理

专利申请获得专利局的受理,将获得申请日和申请号,专利局以专利受理通知书的形式下发,此申请日之后,他人与之相同或相似的技术方案将不能再申请专利。

四、专利的官方审查

发明专利的审查历经五个阶段:受理阶段、初审阶段、公布阶段、实审阶段、授权阶段。
实用新型和外观设计专利的审查历经三个阶段:受理阶段、初审阶段、授权阶段。
专利申请的审查阶段中,专利局会对专利申请提出审查意见,要求申请人予以答复,答复的形式较为专业而且对授权前景起到决定性作用,一般由申请人参与纯技术方面的意见,最终由代理人撰写完整的审查意见答复稿并提交至专利局。
发明专利一般情况下,会有一至两次(或者多次)的审查意见通知书;关于实用新型和外观设计,原则上没有审查意见通知书,但具体情况视专利局实际流程为准,体现在实用新型专利近几年也会出现答复审查意见的情况。

五、专利的授权和专利证书
专利获得授权时,专利局发出授予专利权通知书,申请人需缴纳授权登记费用和授权当年的年费,约两个月左右,申请人将获得专利证书,申请人的技术方案真正获得了法律的保护,成为专利的专利权人。

六、专利权的维护

当申请人的技术获得专利授权后,要想维持专利权的有效,在专利的保护期限内,需要每年缴纳年费,下一年的年费一般需要在上年度申请日之前缴纳。

七、专利的终止

首先,专利的申请与专利权的放弃,均是申请人的自愿行为。
1)专利申请阶段:申请人可以随时撤回专利申请。
2)专利审查阶段:申请人如果没有在期限内完成答复程序,专利申请将被视为撤回。
3)专利授权阶段:申请人可以不缴纳授权登记费,将被视为放弃专利权。
4)专利权阶段:①专利权保护期限过程中,专利权人主动不缴纳年费,专利权终止;②专利权的保护期限届满,专利权终止;③专利权被他人全部无效,专利权视为自始即不存在。

八、可能存在的专利申请被驳回

专利申请的特性之一,即是专利申请特别是发明专利申请并非百分百授权,从另一角度体现了专利的严谨性和科技进步性。

当专利申请出现被驳回情况时,申请人可以通过专利复审的形式,向专利复审委员会提出请求,重新争取机会,复审决定可能存在两种不同的结论:①确认复审请求理由成立,决定撤销专利局原驳回决定,申请转回专利局原审查部门继续审查;②维持专利局原驳回决定,申请人对复审决定不服的,可以向法院起诉,由法院作出最后裁决。

九、可能存在的专利权被无效

中国专利法规定,专利自授权公告之日起,任何单位或者个人认为该专利权的授予不符合专利法有关规定的,可以请求专利复审委员会宣告该专利权无效。

请求人,需要提出无效宣告请求书,详细陈述各条权利无效的理由;专利权人,针对请求人提出的理由,进行有理有据的反驳,并且可以对权利要求书进行相应的修改。

可能存在的结果,①专利权人获得支持,专利权仍然有效;②请求人获得支持,专利权被部分宣告无效或被全部宣告无效,专利权人不服决定的,可以向法院起诉。

情况说明:专利权被提出无效的案例,属于少数行为,其中多出现在企业专利被市场竞争对手提出无效,而且如果自己的技术具备新颖性和创造性的授权条件,那么多数情况下不会被对方无效;因此,普通科研工作者关于申请专利以及专利权的维护,不必过多担心。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-03-18 yangcristina

    嗯,上次申请专利时觉得很繁琐,谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错,有指导作用,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错,有指导作用,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错,有指导作用,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    值得关注,收藏!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=71584, encodeId=c787e15849c, content=嗯,上次申请专利时觉得很繁琐,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:52:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56239, encodeId=1a89562391a, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56240, encodeId=5de85624027, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56241, encodeId=12f456241f6, content=不错,有指导作用,, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56242, encodeId=a54856242f8, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56243, encodeId=79b556243f3, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56244, encodeId=4b5356244d6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56245, encodeId=a52f562451c, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56246, encodeId=0c8b5624685, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56247, encodeId=8fc65624ebf, content=值得关注,收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:24:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    值得关注,收藏!

    0

相关资讯

知识产权将从“云端”走向大众

原标题:知识产权将从“云端”走向大众 知识产权不再是曲高和寡,而将成为人人都要了解的一项技能。昨天举行的上海市知识产权联席会议部署了2015年知识产权工作,其中全力以赴做好市委关于加快建设具有全球影响力的科技创新中心成为重中之重。上海市副市长赵雯表示,知识产权是创新的保障,在全面提倡“大众创业、万众创新”的今天,知识产权将从“云端”走向大众。 尽管本市去年专利申请总量同比下降5.5%,但4

如何看懂—专利文献号

(一)专利文献号专利文献是指国家知识产权局按照法定程序公布的专利申请文件和公告的授权专利文件。专利文献种类是指国家知识产权局按照相关法律法规对发明、实用新型、外观设计专利申请在法定程序中予以公布或公告,由此产生的各种专利文献。专利文献号是指国家知识产权局按照法定程序,在专利申请公布和专利授权公告时给予的专利文献标识号码。特点一件专利申请形成的专利文献至始至终只能获得一个专利文献号;例如:发明专利申

专利申请的十一大误区

随着近几年国家对知识产权的重视,国内的企业对专利在提升核心竞争力方面的作用有了进一步的认识,纷纷加强了专利工作,专利申请量大幅度增加,但是在专利代理过程中,笔者发现不少企业在专利申请过程中,仍存在误区,需要早日改进。误区一:自主研发的成果不申请专利就有知识产权。一些技术人员认为只要是自主创新,就有了自主知识产权。其实不然,专利是一种垄断权,自主研发的技术成果如果不申请专利,就得不到法律确认和保

不丧失专利新颖性的宽限期

一、建议,尽量避免使用不丧失新颖性的宽限期虽然专利法规定了不丧失专利新颖性的宽限期,但小编认为尽量不使用它,原因是:首先对符合规定的展览或会议要求较高,而且必须能出具证明才有效,同时此种公开对自己和他人的技术都会有影响,即公开日并非专利申请日,因此,建议,最好在展出或发表自己的技术之前,先申请专利,获得申请日和申请号之后,再参加展出或会议发表等,这样才能有效保证自己技术的新颖性。如果出于其他原因产

在线课堂:科研工作与知识产权保护系列课程

知识产权也称其为“知识财产权”,是关于人类在社会实践中创造的智力劳动成果的专有权利,是一种无形财产权。它有两类:一类是著作权,也称为版权,另一类是工业产权,也称为产业产权,其中产业产权又主要包括专利权与商标权。知识产权保护是非常重要的。 本系列课程涵盖目前国家非常重视的知识产权领域中的专利问题,课程中江编辑将为大家细致的讲解科研工作者关于认知专利、运用专利等方面的知识,尤其涉及医学、药学以及

案例介绍—医药生物领域的授权专利

1、用于实施疾病诊断和治疗方法的仪器或装置例如:诊断和治疗用的仪器设备或手术器械。案例:一种重叠覆盖椭球体的消融灶产生系统及方法(授权公告号 CN 100484491 C)一种治疗肛瘘的压力控制单向挂线器(授权公告号 CN 100581488 C)医用封堵器抗压能力测试装置(授权公告号 CN 102435501 B)一种多功能医用洗头装置(授权公告号 CN 203263699 U)一种手术撑开